The Woodlands, Texas (August 1, 2014) —Michael Bookman, M.D., an internationally renowned physician specializing in gynecologic cancer, will join Arizona Oncology, a practice in The US Oncology Network, and serve as medical director of the US Oncology Research Gynecology Research Program. In his new role, effective Oct. 6, 2014, Dr. Bookman will use his extensive medical experience to bring more high-priority gynecologic clinical trials to US Oncology Research while managing the gynecologic oncology research portfolio and patient accrual at a national level.
“The appointment of Dr. Bookman is another important step in building The US Oncology Network as the best place to be treated for cancer and the preferred group to bring novel therapies to patients with cancer. Dr. Bookman’s recruitment is an important next step as we strive to prevail over the disease,” said Michael Seiden, chief medical officer, The US Oncology Network. “Offering patients access to cutting-edge clinical trials in a community setting is a critical part of advancing the quality and science of cancer care. I’m confident Dr. Bookman will succeed in helping us to build a world class gynecologic research program that achieves these goals.”
“Our clinical research environment is evolving rapidly, with an emphasis on industry-sponsored trials of molecular targeted agents, often in selected patient populations with predictive biomarkers, using smaller randomized pilots to select and validate promising regimens for definitive Phase III trials,” said Dr. Bookman. “US Oncology Research is uniquely positioned to stay ahead of this trend and offer important trials to patients with a variety of gynecologic cancers, including rare diseases and uncommon molecular subtypes. I look forward to collaborating with our local teams to energize our gynecologic cancer research program and bring the best clinical trials to patients treated within our network.”
Dr. Bookman has more than 25 years of clinical trial experience, encompassing the intramural National Cancer Institute (NCI) program; Gynecologic Oncology Group (GOG); National Comprehensive Cancer Network (NCCN); and positions at two NCI-designated comprehensive cancer centers. His extensive experience includes the multidisciplinary management of gynecologic oncology care, medical informatics, outcomes database development, budget and contract development for clinical research, and regulatory compliance. He continues to serve as Chair of the Ovarian Committee for GOG, which has been integrated with NRG Oncology under the NCI National Clinical Trials Network. He also serves as Director of Educational Resources for the International Gynecologic Cancer Society (IGCS), with a commitment to support meaningful outreach within the developing world.
In addition to his leadership duties with US Oncology Research, Dr. Bookman will begin seeing patients at Arizona Oncology-Tucson, located at 603 N. Wilmot Road, Suite 151.
“Dr. Bookman is a well-respected and well-accomplished physician who is committed to his patients and dedicated to advancing high-quality cancer care,” said Joe Buscema, M.D., practice president, Arizona Oncology. “With more than 25 years of clinical trial experience, he is the perfect fit for our practice and our patients. I look forward to the progress he will make in the area of gynecologic oncology research and am excited to work side-by-side with him in Arizona.”
About Arizona Oncology
Arizona Oncology is one of the largest medical groups in Arizona, with more than 60 practicing physicians devoted exclusively to the most comprehensive, compassionate and quality cancer care to patients in several communities throughout the state, including: Chandler, Cottonwood, Deer Valley, Flagstaff, Glendale, Green Valley, Nogales, Oro Valley, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson. Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit ArizonaOncology.com.
Arizona Oncology is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. As an affiliate of The US Oncology Network, Arizona Oncology is united with nearly 1,000 physicians nationwide. Arizona Oncology participates in clinical trials through US Oncology Research, which has played a role in 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.
About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves nearly 70 research sites and approximately 200 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 58,000 patients in approximately 1,300 trials since inception in 1992 and have played a role in 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information call (800) 482-6700 or visit www.usoncology.com/oncologists.